Presentación de PowerPointproyectos.andi.com.co/cif/Documents/PHARMACEUTICAL...1998 276 4236 1622...

CONTENT

• Introduction - ANDI

• Global Indicators of Pharmaceutical Industry

• Latin America Pharmaceutical Market

• Colombian Pharmaceutical Market

• Total market value in Colombia

• Colombia: Foreign trade

• ANDI’s Monthly Industrial Survey EOIC – DEC 2012

• Changes of the Colombian Economy

• Social indicators in Colombia

• Current legislation

• Conclusions

• Topics in the future of the Pharmaceutical Industry

•Created in 1944

•1100 members from different sectors of the

economy

•28 specialized chambers

•10 regional branches

•We represent our members, as well as the

Colombian private sector in general, before

national and international institutions, dealing

with economic, legal, social and business issues.

•ANDI’s main purpose is to promote an

environment, where firms and markets can

develop properly.

•ANDI is part of a non-profit organization,

created in the city of Medellin in 1944. Since

then, it has always been the most important

private sector association.

•ANDI gathers more than 1100 companies

that belong to different sectors of the

economy, representing about 46% of the

Colombian GDP.

•We have 28 specialized chambers as

follows:

•Mining

•Steel

•Legal services

•Health

•Food industry

•Cosmetics

•Farmaceutical

•Fishing industries-among others-

REGIONAL

We have 10 regional

branches around the country

located in:

•Cartagena

•Barranquilla

•Medellin

•Pereira

•Bucaramanga

•Manizales

•Ibague

•Cali

•Bogota

•Valle del cauca

RODRIGO ARCILA GÓMEZ

Director Ejecutivo Cámara Farmacéutica

PHARMACEUTICAL INDUSTRY IN

COLOMBIA

The Pharmaceutical Industry in the world

The pharmaceutical expenditure will get US$ 1.2 billions in 2016

Source: IMS Health Market Prognosis (includes IMS Audited and Unaudited markets) All information current as of March, 2009

Source: IMS Health Market Prognosis, March 2011

Total mercados globales auditados y no auditados

2011 2011 2007-2011 2012 2012-2016

Tamaño del mercado US$ Bn

% Crecimiento const. Us $ Carg % Const

US$ Proyección % en

crecimiento Carg % Const

US$

$955.5 5.1% 6.1% 3 - 4% 3 - 6%

Total mercados globales auditados y no auditados

2011 2010 2007-2011 2012 2012-2016

Tamaño del mercado US$ Bn

% Crecimiento const. Us $

% Crecimiento const. Us $

Carg % Const US$

Proyección % en crecimiento

Carg % Const US$

Norte América $347.1 3.0%

2.2% 3.5% 1 - 2% 1 - 4%

Europa $265.4 2,4% 2.9% 4.9% 0 - 1% 0 - 3%

Asia/Africa/Australia $165.2 13.1% 14.0% 15.5% 10 - 11% 10 - 13%

Japon $111.2 5.6% 0.1% 3.9% 0 - 1% 1 - 4%

Latin America $66.7 8.9% 12.7% 12.3% 13 - 14% 10 - 13%

Source: IMS HEALTH

397 434 500 560

605651

720788 819 856

95512,1%9,1%

9,1%

7,6%

7,2% 7,0% 6,9%6,1%

7,1%

4,1%

4,50%

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

The global anual growth will increse from US$ 30,000 to Us$ 70,000 millions per year in the nex five years

Fuente: IMS Market Prognosis, abril de 2012

China is still being the biggest and it is having the fastest growth among emergency pharmatheutical markets.

//upload.wikimedia.org/wikipedia/commons/6/63/Latin_America_(orthographic_projection).svg

Fuente: IMS MIDAS; Análisis de IMS Health

Todos los datos en el MAT Q1 del año.

Fuente: IMS MIDAS; Bancos Centrales de los países; Análisis de IMS Health

Todos los datos en el MAT Q1 del año. Valores expresados a nivel Ex-Manufacturer de IMS MIDAS.

Valores expresados en dólar constante, en base a la tasa del 25 de mayo de 2012. *Descontada la

inflación.

Source: IMS HEALTH

HEALTH EXPENDITURE (% OF GDP)

Source: The World Bank

AÑO

América Latina y el

Caribe

Estados Unidos

Unión Europea

Brasil Chile Ecuador Venezuela Argentina Colombia Guatemala Nicaragua

1995 243 3748 1664 316 264 73 143 617 186 54 57

1996 259 3900 1702 350 300 81 106 620 230 56 58

1997 278 4055 1568 356 330 88 144 671 270 64 48

1998 276 4236 1622 336 338 83 176 688 239 77 53

1999 253 4450 1630 242 316 65 231 707 206 79 51

2000 269 4703 1500 265 324 54 273 689 161 95 54

2001 264 5052 1548 228 298 79 295 678 156 99 54

2002 222 5453 1732 203 288 97 207 225 150 103 57

2003 229 5588 2165 214 346 110 190 283 146 111 61

2004 264 5911 2493 257 419 130 239 332 173 119 66

2005 335 6259 2636 387 501 147 296 400 211 132 71

2006 400 7073 2798 492 592 205 388 464 273 171 78

2007 479 7437 3186 610 683 228 477 562 337 184 93

2008 551 7720 3523 715 765 270 598 698 377 199 105

2009 555 7960 3420 734 802 321 688 734 392 184 104

2010 670 8362 3368 990 947 328 663 742 472 196 103

HEALTH EXPENDITURE PER CAPITA

(CURRENT US$)


PUBLIC HEALTH EXPENDITURE (% OF TOTAL HEALTH EXPENDITURE)


Fuente: IMS

The Colombian pharmaceutical market shows a growth of 5% in units for the MAT May 2012, The generic evolution has been slowed although they are the main growing source.

Fuente: IMS

In valiues the total market reached to USD$ 2.255 MM the generic grew 2 points above the brand average in the last year.

Fuente: IMS

Historically the OTC market has grown above the rest of the segments; however, in the last year the milks overcome OTC and Rx.

Fuente: IMS

The growth for the next years is aligned with the economy growth expectations

TOTAL MARKET VALUE (TRADE AND INSTITUTIONAL) IN COLOMBIA

SALES TRADE MARKET (POPULAR + ÉTICO) IN COLOMBIAN PESOS

AÑO MERCADO POPULAR MERCADO ETICO TOTAL

2006 798.191.488.774 2.267.058.432.750 3.065.249.921.524

2007 971.694.434.865 2.163.147.791.255 3.134.842.226.120

2008 1.082.201.205.166 2.311.776.037.851 3.393.977.243.017

2009 1.179.111.453.237 2.311.317.280.544 3.490.428.733.781

2010 1.306.130.086.328 2.421.470.553.363 3.727.600.639.691

2011 1.439.183.677.636 2.567.892.280.808 4.007.075.958.444

2012 1.560.477.999.171 2.589.576.539.311 4.150.054.538.482

Source: IMS HEALTH. MAT DEC

SALES TRADE AND INSTITUCIONAL MARKET IN COLOMBIAN PESOS

AÑO TOTAL MERCADO TRADE TOTAL MERCADO INSTITUCIONAL

TOTAL DEL MERCADO

2006 3.065.249.921.524 1.379.362.464.686 4.444.612.386.210

2007 3.134.842.226.120 1.410.679.001.754 4.545.521.227.874

2008 3.393.977.243.017 1.527.289.759.358 4.921.267.002.375

2009 3.490.428.733.781 1.570.692.930.201 5.061.121.663.982

2010 3.727.600.639.691 1.677.420.287.861 5.405.020.927.552

2011 4.007.075.958.444 1.803.184.181.300 5.810.260.139.744

2012 4.150.054.538.482 1.867.524.542.317 6.017.579.080.798

Source: IMS HEALTH.MAT DEC. We estimated the institutional market as 0,45 percent of the trade market.

Total pharmaceutical Market Brands vs. Generics

Pesos (MM)

Total pharmaceutical Market Brands vs. Generics

Units (MM)

Fuente: IMS-Cámara de la Industria Farmacéutica ANDI


Total Pharmaceutical Market Millions of Pesos (000,000,000)

Total pharmaceutical Market Millions unist (000,000)



Total Pharmaceutical Market Growth Elements

Valores en USD

Posición Producto MTH Dec-12 MAT Dec-12 YTD Dec-12

1. Jabon Protex (25) 705.750 8.513.244 8.513.244

2. Dolex (30) 3.987.252 49.434.290 49.434.290

3. Klim (32) 3.197.846 39.184.223 39.184.223

4. Pedialyte 30 (6) 777.404 9.125.094 9.125.094

5. Cloruro De Sodio -

bax (5) 212.735 2.705.591 2.705.591

6. Talco Mexsana (21) 969.464 11.088.880 11.088.880

7. Listerine (32) 907.045 11.061.950 11.061.950

8. Johnson Jabon (11) 156.230 1.878.612 1.878.612

9. Chapstick (13) 696.366 7.175.687 7.175.687

10. Diclofenac Mk 164.675 1.813.998 1.813.998

Principales Productos Totales por Valores

en Ventas


TOP 10 PRODUCTS SALES DEC2012


Cámara de la Industria

Farmacéutica

Valores en USD


1. Cloruro De Sodio- bax (5) 212.735 2.705.591 2.705.591

2. Diclofenac Mk 164.675 1.813.998 1.813.998

3. Omeprazol- gef (1) 100.238 1.075.925 1.075.925

4. Omeprazol- lst (1) 60.855 1.011.733 1.011.733

5. Sildenafil Mk 185.886 2.357.171 2.357.171

6. Travad (3) 495.154 7.062.012 7.062.012

7. Sildenafil - lst (2) 62.812 784.944 784.944

8. Sildenafil - lfc (4) 61.622 873.953 873.953

9. Postday (1) 636.063 7.784.217 7.784.217

10. Acetaminofen - lfc (4) 80.958 1.212.752 1.212.752

Principales Productos del Mercado Ético

por Valores en Ventas


TOP 10 PRODUCTS ETHICAL MARKET SALES DEC 2012


Farmacéutica

Valores en USD


1. Jabon Protex (25) 705.750 8.513.244 8.513.244

2. Dolex (30) 3.987.252 49.434.290 49.434.290

3. Klim (32) 3.197.846 39.184.223 39.184.223

4. Pedialyte 30 (6) 777.404 9.125.094 9.125.094

5. Talco Mexsana (21) 969.464 11.088.880 11.088.880

6. Listerine (32) 907.045 11.061.950 11.061.950

7. Johnson Jabon (11) 156.230 1.878.612 1.878.612

8. Chapstick (13) 696.366 7.175.687 7.175.687

9. Emulsion De Scott (15) 455.467 7.923.839 7.923.839

10. Asepxia (20) 548.837 5.957.863 5.957.863

Principales Productos del Mercado Popular

por Valores en Ventas

Fuente: IMS-Cámara de la Industria Farmacéutica ANDI Fuente: IMS-Cámara de la Industria Farmacéutica ANDI

TOP 10 PRODUCTS POPULAR MARKET SALES DEC 2012


Farmacéutica

Valores en Pesos Colombianos

Posición Laboratorio PESOS % CRECIMIENTO

1 LAFRANCOL 249.411.426.063 6,01 1,87

2 GLAXOSMITHKLINE 196.367.691.419 4,73 -1,39

3 NESTLE 166.367.391.433 4,01 5,86

4 ABBOTT 166.271.335.924 4,01 8,21

5 MSD 161.135.940.985 3,88 -1,88

6 PFIZER 161.059.560.220 3,88 -8,87

7 BAYER PHARMACEUTIC 160.724.936.684 3,87 -5,15

8 SANOFI 140.766.413.962 3,39 -2,85

9 MCKESSON 136.852.808.068 3,30 3,50

10 GENFAR 126.743.556.273 3,05 9,72


Principales Laboratorios por Valores en

Ventas


TOP 10 LABORATORIES SALES DEC 2012 Cámara de la Industria

Farmacéutica

Colombia: Contribution from each sector to the Manufacturing Industry Production 2010

Number of labs audited by DANE (National Statistic Deparment) in the Pharmaceutical Industry in Colombia

DANE-DIAN. Cálculos Cámara Farmacéutica - ANDI

Source: Encuesta Anual Manufacturera DANE-Cálculos: Cámara

Farmacéutica ANDI

Gross Production of the Pharmaceutical Industry in Colombia (Millions of Pesos)

Source: Encuesta Anual Manufacturera

DANE-Cálculos: Cámara Farmacéutica

ANDI

17.837 18.617 20.138

21.300 22.664 23.239 24.015 23.239 23.768

0

5.000

10.000

15.000

20.000

25.000

30.000

2002 2003 2004 2005 2006 2007 2008 2009 2010

Total number of employees in the Pharmaceutical Industry in Colombia

Source: Encuesta Anual Manufacturera DANE-Cálculos: Cámara

Farmacéutica ANDI

Participation of the Pharmaceutical Industry total Assets of the Manufacturing Industry


DANE-Cálculos: Cámara Farmacéutica ANDI

Apparent Consumption in the Pharmaceutical Industry in Colombia (Millions of Dollars)



FOREIGN TRADE

Export Rate of the Pharmaceutical Industry in Colombia – Percentage of the production that covers the external



Import Rate of the Pharmaceutical Industry in Colombia- Percentage



* To December 2012

TOTAL EXPORTS OF THE PHARMACEUTICAL INDUSTRY

IN COLOMBIA

20032004

20052006

20072008

20092010

20112012

0,00

50,00

100,00

150,00

200,00

250,00

300,00

350,00

400,00

450,00

210,14 205,76

242,02

270,47 283,28

343,54

391,21

347,06

387,07

433,12

Valores en millones ($US FOB)

Fuente: Bases Exportaciones DIAN Calculos: Cámara Farmacéutica ANDI

*To December 2012

TOTAL IMPORTS OF THE PHARMACEUTICAL INDUSTRY IN

COLOMBIA

20032004

20052006

20072008

20092010

20112012

0,00

500,00

1000,00

1500,00

2000,00

2500,00

537,57

592,15 592,69

735,67

861,37

1037,87

1261,51

1419,60

1631,95

2008,16


Valores en millones ($US CIF)


Valores en millones ($US CIF)

INCIDENCE AND GROWTH

OF PATHOLOGIES IN

COLOMBIA

Diabetes / Renal Disease

Segments 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

CAGR

%

(2006 -

2013)

Prevalence of Diabetes

(Thousand) 1.050 1.099 1.149 1.201 1.254 1.309 1.365 1.423 1.481 1.541 1.601 1.662 4,1

Prevalence Percent of

Diabetes 3 3 3 3 3 3 3 3 3 3 3 4 2,7

Incidence of Diabetes 55.605 57.840 60.126 62.179 64.228 66.085 67.973 69.853 71.424 72.840 74.260 75.378 2,3

Renal Failure

Prevalence 11.925 12.187 12.465 12.759 13.070 13.400 13.748 14.116 14.506 14.918 15.354 15.814 2,8

Fuente: Frost & Sullivan

Respiratory Disease

Segments 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 CAGR % (2006 - 2013)

Prevalence of Asthma (Thousand)

3.060,0 3.137,0 3.216,0 3.298,0 3.382,0 3.469,0 3.559,0 3.652,0 3.748,0 3.848,0 3.952,0 4.059,0 2,6

Prevalence percent of Asthma

7,5 7,5 7,6 7,7 7,8 7,8 7,9 8,0 8,1 8,2 8,3 8,5 1,2

Prevalence of Chronic Obstructive Pulmonary

Disease (COPD) (Thousand) 1.989,0 2.041,0 2.100,0 2.163,0 2.229,0 2.299,0 2.372,0 2.449,0 2.530,0 2.615,0 2.705,0 2.800,0 3,3

Mortality due to Asthma, Bronchitis and Emphysema

11.429,0 12.198,0 13.029,0 13.926,0 14.895,0 15.943,0 17.078,0 18.306,0 19.637,0 21.079,0 22.644,0 24.343,0 7,3

Mortality due to Respiratory Disease

9.681,0 9.983,0 10.298,0 10.627,0 10.970,0 11.329,0 11.703,0 12.095,0 12.504,0 12.932,0 13.380,0 13.848,0 3,4

Fuente: Frost & Sullivan

ANDI’S MONTHLY INDUSTRIAL

SURVEY EOIC

JANUARY 2013

GROWTH JANUARY- 2013

Source: EOIC ANDI

-30

-20

-10

0

10

20

30

en

e-0

0

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

FARMACEUTICO TOTAL EOIC

Fuente: Encuesta de Opinión Industrial Conjunta

Fuente: EOIC ANDI

TOTAL PHARMACEUTICAL PRODUCTION VS TOTAL MANUFACTURING INDUSTRY JAN 2013

Fuente: EOIC ANDI

-30

-20

-10

0

10

20

30

40

en

e-0

0

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

PRODUCCION VENTAS


PHARMACEUTICAL SECTOR SALES AND PRODUCTION VARIATION YEAR TO DATE JAN 2013

Fuente: EOIC ANDI

50

55

60

65

70

75

80

85

90

95

100e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

E


PHARMACEUTICAL SECTOR PERCENTAGE OF INSTALLED CAPACITY JAN 2013

-20

0

20

40

60

80

100

120e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

ALTOS INVENTARIOS PEDIDOS ALTOS O NORMALES


Fuente: EOIC ANDI

INDICATORS OF THE PHARMACEUTICAL SECTOR DEMAND JAN 2013

Fuente: EOIC ANDI

0

20

40

60

80

100

120e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

SITUACION ACTUAL REGULAR O MALA MEJORES EXPECTATIVAS PROXIMOS SEIS MESES


PHARMACEUTICAL SECTOR BUSSINESS ENVIROMENT JAN 2013

12,5

12,5

12,5

12,5

12,5

37,5

0 10 20 30 40

Legislación

Cartera

Falta de tecnología

Demanda

Competencia

Tipo de Cambio


Fuente: EOIC ANDI


MAIN PROBLEMS OF THE PHARMACEUTICAL SECTOR JAN 2013

0

10

20

30

40

50

60

70

80

90e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je


PROBLEMS OF DEMAND IN THE PHARMACEUTICAL SECTOR JAN 2013

Fuente: EOIC ANDI

-10

0

10

20

30

40

50e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

E


PROBLEMS OF LOW PORTFOLIO TURNOVER IN THE PHARMACEUTICAL SECTOR JAN 2013

-5

0

5

10

15

20

25

30

35e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je


PROBLEMS OF WORKING CAPITAL IN THE PHARMACEUTICAL SECTOR JAN 2013

-10

0

10

20

30

40

50

60e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je


PROBLEMS OF EXCHANGE RATE IN THE PHARMACEUTICAL SECTOR JAN 2013

0,0

5,0

10,0

15,0

20,0

25,0

30,0

35,0

40,0

45,0e

ne

-00

en

e-0

1

en

e-0

2

en

e-0

3

en

e-0

4

en

e-0

5

en

e-0

6

en

e-0

7

en

e-0

8

en

e-0

9

en

e-1

0

en

e-1

1

en

e-1

2

en

e-1

3

Po

rce

nta

je

Fuente: DANE

PUBLIC ORDER PROBLEMS IN THE PHARMACEUTICAL SECTOR JAN 2013

CHANGES OF THE

COLOMBIAN ECONOMY


Farmacéutica

COLOMBIA: FOREIGN TRADE MILLIONS US$

2012 2011 Ene-Nov Nov

Exportaciones Totales 54.690 51.452 6,3 -8,2

Tradicionales 37.690 36.006 4,7 -14,6

Café 1.750 2.337 -25,1 -41,7

Petróleo 27.891 25.266 10,4 -13,8

Carbón 7.239 7.640 -5,2 -12,4

Ferroníquel 810 763 6,1 26,2

No Tradicionales 16.999 15.446 10,1 7,0

Industriales 21.713 20.872 4,0 -1,6

2012 2011 Ene-Nov NovImportaciones Totales 54.152 50.170 7,9 2,1

Bienes de Consumo 11.597 10.350 12,1 4,3

Bienes Intermedios 23.385 21.095 10,9 -0,2

Bienes de Capital 19.145 18.700 2,4 3,3

Para la industria 10.489 9.532 10,0 0,0

Maquinaria industrial 4.420 4.014 10,1 -1,3

Enero-Noviembre Variación %

Enero - Noviembre Variación %

Enero-Noviembre (Millones US$)

2012 2011 Valor Ene-Nov Nov 2012 2011

Total 56.954 54.690 51.452 3.237 6,3 -8,2 100 100

Países con reduccion en exportaciones

Italia 745 440 694 -254 -36,6 -0,5 0,8 1,3

Dinamarca 451 178 398 -220 -55,2 0,0 0,3 0,8

Países Bajos 2.524 2.107 2.307 -200 -8,7 2,8 3,9 4,5

Chile 2.205 1.862 2.054 -192 -9,3 -0,2 3,4 4,0

Japón 528 334 505 -171 -33,8 -0,3 0,6 1,0

Costa Rica 435 254 413 -159 -38,5 0,1 0,5 0,8

Canadá 614 432 560 -127 -22,7 0,1 0,8 1,1

Bélgica 621 444 560 -116 -20,7 -0,4 0,8 1,1

Reino Unido 1.196 1.029 1.108 -78 -7,1 -0,4 1,9 2,2

Brasil 1.370 1.201 1.271 -71 -5,6 -0,2 2,2 2,5

Subtotal 12.423 9.506 11.357 -1.851

Países con aumento en exportaciones

España 1.720 2.754 1.400 1354 96,7 -2,1 5,0 2,7

Resto de países 11.139 11.133 9.931 1202 12,1 3,7 20,4 19,3

China 1.989 2.878 1.821 1057 58,1 2,5 5,3 3,5

Venezuela 1.750 2.516 1.553 963 62,0 0,6 4,6 3,0

Estados Unidos 21.705 19.914 19.752 162 0,8 -11,5 36,4 38,4

Perú 1.397 1.407 1.254 152 12,1 -1,0 2,6 2,4

Ecuador 1.909 1.878 1.738 140 8,1 0,3 3,4 3,4

México 705 777 642 135 21,1 0,1 1,4 1,2

Subtotal 43.577 44.505 39.254 5.250

FUENTE: DANE, Cálculos ANDI

EXPORTACIONES TOTALES Enero-Noviembre (US$ Millones)

Año 2011Valor Participación Variación

TOTAL EXPORTS (JANUARY – NOVEMBER, MILLIONS US$)

Valor % 2011 2010

Total 14.468 15.446 13.070 2376 18,2 100,0 100,0

Total (excl Venezuela) 14.467 15.439 13.068 2371 18,1

Países con reduccion en exportaciones

Portugal 56 31 53 -22 -41,5 0,2 0,4

Francia 57 38 51 -13 -25,4 0,2 0,4

Puerto Rico 128 103 117 -13 -11,5 0,7 0,9

Subtotal 510 418 469 -52

Países con aumento en exportaciones

Estados Unidos 4.117 4.222 3.655 567 15,5 27,3 28,0

Resto de países 1.679 1.881 1.541 341 22,1 12,2 11,8

Ecuador 1.586 1.678 1.431 247 17,2 10,9 11,0

Brasil 653 806 604 201 33,3 5,2 4,6

Perú 920 960 832 128 15,4 6,2 6,4

Venezuela 1.213 1.239 1.114 125 11,3 8,0 8,5

Suiza 837 830 722 107 14,9 5,4 5,5

Alemania 159 247 148 99 66,9 1,6 1,1

Chile 422 473 384 89 23,1 3,1 2,9

Países Bajos 124 200 115 85 73,8 1,3 0,9

México 496 545 460 84 18,3 3,5 3,5

Italia 192 262 178 84 47,0 1,7 1,4

Bélgica 210 236 192 44 23,0 1,5 1,5

Bolivia 106 128 97 32 32,7 0,8 0,7

Argentina 90 112 83 29 35,3 0,7 0,6

China 284 290 262 29 11,0 1,9 2,0

Subtotal 13.959 15.028 12.601 2.428

Fuente: DANE - DIAN, Cálculos: ANDI

Año 2010 2011 2010Variación Participación

EXPORTACIONES NO TRADICIONALES (Enero-Noviembre US$ Millones)

NON TRADITIONAL EXPORTS (JANUARY – NOVEMBER, MILLIONS US$)

EXPORTS BY ECONOMIC ACTIVITY JAN-NOV (MILLIONS US$)

2012 2011 Part

Ene-Nov Nov

TOTAL 54.690 51.452 6,3 -8,2 100,0

AGROPECUARIO 2.435 2.119 14,9 32,0 4,5

MINERIA 30.430 28.321 7,4 -15,2 55,6

INDUSTRIA 21.713 20.872 4,0 -1,6 39,7

Alimentos y bebidas 3 680 4 283 -14,1 -27,4 6,7

Carne y pescado 249 201 24,0 -12,3 0,5Frutas, legumbres, aceites 330 352 -6,4 99,4 0,6Productos de café 2 022 2 647 -23,6 -39,4 3,7Ingenios, refinerías de azúcar 464 516 -10,0 -56,4 0,8Otros productos alimenticios 436 409 6,5 8,3 0,8

Textiles 509 523 -2,8 -1,8 0,9Confecciones 534 484 10,4 1,2 1,0Cuero y sus productos 233 240 -3,0 -8,6 0,4Papel y sus productos 515 502 2,6 10,4 0,9Imprentas y editoriales 157 170 -7,6 15,2 0,3

EXPORTACIONES SEGÚN ACTIVIDAD ECONOMICA

Enero-Noviembre (Millones US$)

Variación %

Source: DANE

COLOMBIA: MAIN INDICATORS


Farmacéutica

COLOMBIA: MAIN INDICATORS

Source: DANE

CONSUMER INFLATION

Source: DANE

POND Enero 2011 Enero 2012 Anual

AGROPECUARIO 7,20 1,67 3,13 2,91

INDUSTRIA 35,11 0,38 0,36 2,15

ALIM. MANUFACTURADOS 11,98 0,84 0,98 5,20

BEBIDAS Y TABACO 2,22 0,25 0,19 4,66

TEXTILES, CONFEC Y CUERO 5,03 0,02 0,10 0,41

MUEBLES DE MADERA 0,60 -0,07 0,24 -0,01

PAPEL E IMPRENTAS 1,23 0,06 0,30 1,94

INDUSTRIA QUIMICA 6,54 0,46 0,34 1,98

SECTOR METALMECÁNICO 6,35 -0,20 -0,54 -3,29

OTRAS INDUSTRIAS 1,16 -0,04 0,39 2,18

SERVICIOS PRIVADOS 34,06 0,67 0,63 3,96

BIENES PUBLICOS 23,63 1,04 1,45 5,06

TOTAL SIN ALIMENTOS 100,00 0,31 2,95 3,73

TOTAL 100,00 0,73 0,91 3,54

INFLACIÓN AL CONSUMIDOR SEGÚN ORIGEN (%)

PRODUCER AND CONSUMER INFLATION

Source: DANE

SOCIAL INDICATORS IN

COLOMBIA

UNEMPLOYMENT RATE IN COLOMBIA (TO DECEMBER)

Fuente: Así Vamos en Salud.

HEALTH AFFILIATES GEOREFERENCIADO IN COLOMBIA

Fuente: Así Vamos en Salud.

CURRENT LEGISLATION

Law 100 of 1993

The new SGSSS health reform

Law 1122 of 2007

Law 1438 of 2001

Resolution 1403 of 2007

Decree 3050 of 2005

Decree 3636

Health Regulatory Commission

National Commission of Medicine Prices

CONCLUSIONS

The participants in the pharmaceutical market and the production are

growing.

As far as the other sectors of the colombian economy grow, demand for

health services and social security coverage increases.

The pharmaceutical industry contributes to create more employment

Salaries in the pharmaceutical industry now are in balance in relation with

the manufacturing industry

The pharmaceutical sector in Colombia is not as open as it could be

The trend of Assets value is increasing.

The apparent consumption is one of the main indicators in the sector.

The internationalization of the colombian pharmaceutical market in still

reduced and has a lot of space to grow.

Exports and imports continue to grow. In 2010 Venezuela for the first time

ceased to be the first destination, which this place is now held by Ecuador.

Origin and destination of the colombian market are diversified.

The sales ratio of RX and OTC in the last three years remain relatively

stable.

The best future growth scenarios are in Emerging Countries such as Latin

America.

There is a global trend in the growth of the outsourcing market, not only in

research and development but also in manufacturing, sales and services.

Health expenditure as percentage of GDP is significant.

Out of pocket health expenditure is decreasing.

Equality in the health system is improving.

Institutions in health system need to be reinforced.

The actors in health system have to be more strategic than ever.

Market regulation, macroeconomic enviroment and the managment of

health institutions will determine the future of the system.

High tech will be very useful for the system sustainability.

Economic growth

Changes in the population pyramid

Social Security coverage

Greater access to medicines

Product innovation

More substances classified as OTC

Greater knowledge on behalf of the patient – Selfcare

Distribution channels

More transparency in regulation

Increase in high tech in order to optimize the budget of the health system

Presentación de PowerPointproyectos.andi.com.co/cif/Documents/PHARMACEUTICAL...1998 276 4236 1622...

Documents

Transcript of Presentación de PowerPointproyectos.andi.com.co/cif/Documents/PHARMACEUTICAL...1998 276 4236 1622...